Fertin Pharma Launches Nicotine Science Center

Today, world leading developer and manufacturer of medicated chewing gum, the Danish company Fertin Pharma, launches a new science center: Nicotine Science Center. The Center will fund and facilitate research projects that increase insight into nicotine.

Tobacco use is one of the biggest threats to global public health. Currently, there are more than one billion smokers in the world that would benefit from quitting tobacco. Effective aid to tobacco cessation is therefore of utmost importance.

“Over the last 25 years Fertin Pharma has made a consistent and dedicated effort to continuously develop nicotine gum of improved quality and efficacy for tobacco cessation”, says Søren Birn, CEO Fertin Pharma, and continues: “we need engaged partners and scientists within our research areas to realize our ambition of continuously developing next generation products providing smokers access to more and more efficient smoking cessation treatment. Therefore, we have decided to fund and facilitate this important field of research through the Nicotine Science Center”.

The Nicotine Science Center is placed at Fertin Pharma’s headquarters in Vejle, Denmark, and also has a department in Mumbai, India. The Center is already involved in research projects with Danish and European Universities and this autumn a round of applications will be opened up.

Furthermore, the center has appointed a scientific advisory board consisting of three leading professionals in nicotine related topics or oral drug delivery systems. This board will contribute with key insight into our research areas.

“It is a well-known fact that tobacco users may benefit from Nicotine Replacement Therapy when trying to quit or reduce their use of tobacco products. To accelerate and improve the likelihood of cessation success, we need an increased scientific insight into nicotine and its delivery. The Nicotine Science Center is part of the solution to this puzzle and will contribute with new discoveries”, says head of the scientific advisory board, M.D. Ph. D Philip Tønnesen.

Vice chairman of the Liberal Party in Denmark, former tax minister, Kristian Jensen, will be speaking at the opening of the Center. He is proud that a Danish company is now launching an international science center to contribute to the development of even better NRT-products: “Fertin Pharma is a Danish, family-owned company, which has succeeded in a major transformation from being a manufacturer and developer of regular chewing gum to becoming a world leader in the manufacturing and development of medicated chewing gum. Fertin Pharma has shown a strong commitment to innovation and is therefore one of the companies, which we want to give better conditions for growth e.g. a unitary patent protection in Europe” says Kristian Jensen.

Facts about the Nicotine Science Center:

- Location: Based in Vejle, Denmark. Division in Mumbai, India.
- Affiliated with: Fertin Pharma A/S
- Scientific Advisory Board: M.D. Ph. D and head of the board Philip Tønnesen, Danish Center of Sleep Medicine, Glostrup Hospital. Professor, Andreas Bernkop-Schnürch, University of Innsbruck, Austria. Professor Rainer Müller, Freie University, Germany.
- Next application round: Autumn 2014, 1 million Danish kroner
- Current research partners: Denmark: University of Copenhagen, Aalborg University, Technical University of Denmark. Germany: University of Münster. Sweden: Lund University.

For further information:
Fertin Pharma A/S, press contact Lisbeth Mikkelsen, +45 25334402